References
- Baumann, K. L., Butler, D. E., Deering, C. F., Mennen, K. E., Millar, A., Nanninga, T. N., Palmer, C. W., and Roth, B. D. (1992). The convergent synthesis of CI-981, an optically active, highly potent, tissue selective inhibitor of HMG-CoA reductase. Tetrahedron Lett. 33, 2283-2284 https://doi.org/10.1016/S0040-4039(00)74190-6
- Brazil, M. (2002). A new use for statins? Nature Reviews Drug Discovery 1, 934 https://doi.org/10.1038/nrd977
- Brower, P. L., Butler, D. E., Deering, C. F., Le, T. V., Millar, A., Nanninga, T. N., and Roth, B. D. (1992). The synthesis of (4R-cis)-1,1-dimethylethyl-6-cyanomethyl-2,2-dimethyl- 1,3-dioxane-4-acetate, a key intermediate for the preparation of CI-981, a highly potent, tissue selective inhibitor of HMG-CoA reductase. Tetrahedron Lett. 33, 2279-2282 https://doi.org/10.1016/S0040-4039(00)74189-X
- Butler, D. E., Deering, C. F., Millar, A., Nanninga, T. N., and Roth, B. D. (1989). Improved process for trans-6-[2-(substituted- pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis. W.O. Patent 89/07598
- Butler, D. E., Dejong, R. L., Nelson, J. D., Pamment, M. G., and Stuk, T. L. (2002). Novel Process for the synthesis of 5-(4-Fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydropyran- 2-yl)ethyl]-2-isopropyl-4-phenyl-1H-pyrrole- 3-carboxylic acid phenylamide. W.O. Patent 02/055519
- Graul, A., and Castaner, J. (1997). Atorvastatin calcium. Drugs Future. 22, 956-968 https://doi.org/10.1358/dof.1997.022.09.423212
- Kathawala, F. G. (1991). HMG-CoA reductase inhibitors: An exciting development in the treatment of hyperlipoproteinemia. Med. Res. Rev. 11, 121-146
- Moody, D. J., and Wiffen, J. W. (2005). Process and intermediate compound useful in the preparation of statins, particularly atorvastatin. W.O. Patent 05/012246
-
Moore, R. N., Bigam, G., Chan, J. K., Hogg, A. M., Nakashima, T. T., and Vederas, J. C. (1985). Biosynthesis of the hypocholesterolemic agent mevinolin by Aspergillus terreus. Determination of the origin of carbon, hydrogen, and oxygen atoms by
$^{13}C$ NMR and mass spectrometry. J. Am. Chem. Soc. 107, 3694-3701 https://doi.org/10.1021/ja00298a046 - Park, W. K. C., Kennedy, R. M., Larsen, S. D., Miller, S., Roth, B. D., Song, Y., Steinbaugh, B. A., Sun, K., Tait, B. D., Kowala, M. C., Trivedi, B. K., Auerbach, B., Askew, V., Dillon, L., Hanselman, J. C., Lin, Z., Lu, G. H., Robertson, A., and Sekerke, C. (2008). Hepatoselectivity of statins: Design and synthesis of 4-sulfamoylpyrroles as HMG-CoA reductase inhibitors. Bioorg. Med. Chem. Lett. 18, 1151-1156 https://doi.org/10.1016/j.bmcl.2007.11.124
- Roth, B. D., and Mich, A. A. (1987). Trans-6-[2-(3- or 4-carboxamido- substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis. U.S. Patent 4,681,893
- Roth, B. D., Sliskovic, D. R., and Trivedi, B. K. (1989). Treatment of hypercholesterolemia. Annu. Rep. Med. Chem. 24, 147-156 https://doi.org/10.1016/S0065-7743(08)60538-2
- Roth, B. D., Blankley, C. J., Chucholowski, A. W., Ferguson, E., Hoefle, M. L., Ortwine, D. F., Newton, R. S., Sekerke, C. S., Sliskovic, D. R., Stratton, C. D., and Wilson, M. W. (1991). Inhibitors of cholesterol biosynthesis. 3. Tetrahydro-4-hydroxy-6-[2-(1H-pyrrol-1-yl)ethyl]-2H-pyran- 2-one inhibitors of HMG-CoA reductase. 2. Effects of introducing substituents at positions three and four of the pyrrole nucleus. J. Med. Chem. 34, 357-366 https://doi.org/10.1021/jm00105a056
-
Roth, B. D., and Mich, A. A. (1993). [R-(R*,R*)]-2-(4-Fluorophenyl)-
${\beta},{\delta}$ -dihydroxy-5-(1-methylethyl-3-phenyl-4- [(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof. U.S. Patent 5,273,995 - Sattigeri, J. A., Salman, M., Rawat, S., and Sethi, S. (2005). Process for the preparation of atorvastatin. W.O. Patent 05/118536
- Srinath, S., Mathew, J., Ujire, S., Sridharan, M., and Sambasivam, G. (2002). Process for the atorvastatin form V and phenylboronates as intermediate compounds. W.O. Patent 02/057274
-
Wade, R. A., Zennie, T. M., Briggs, C. A., Jennings, R. A., Nanninga, T. N., Palmer, C. W., and Ronald, J. C. (1997). In pursuit of higher purity: Use of
$^{13}C$ NMR and$^{13}C$ -enriched substrates to trace impurity generation and removal in the synthesis of atorvastatin. Org. Process. Res. Dev. 1, 320-324 https://doi.org/10.1021/op9701088
Cited by
- Ionic tagged amine supported on magnetic nanoparticles: synthesis and application for versatile catalytic Knoevenagel condensation in water vol.4, pp.63, 2014, https://doi.org/10.1039/C4RA05540C
- Isolation of oxidative degradation products of atorvastatin with supercritical fluid chromatography vol.29, pp.12, 2015, https://doi.org/10.1002/bmc.3513
- Magnetic nanoparticle supported amine: An efficient and environmental benign catalyst for versatile Knoevenagel condensation under ultrasound irradiation vol.18, pp.2, 2015, https://doi.org/10.1016/j.crci.2014.05.012
- A simplified catalytic system for direct catalytic asymmetric aldol reaction of thioamides; application to an enantioselective synthesis of atorvastatin vol.67, pp.35, 2011, https://doi.org/10.1016/j.tet.2011.05.109
- Novel DABCO Based Ionic Liquids: Green and Efficient Catalysts with Dual Catalytic Roles for Aqueous Knoevenagel Condensation vol.53, pp.14, 2014, https://doi.org/10.1021/ie500440w
- Concise synthesis of atorvastatin lactone under high-speed vibration milling conditions vol.1, pp.5, 2014, https://doi.org/10.1039/C4QO00052H
- Cooperative Asymmetric Catalysis Using Thioamides toward Truly Practical Organic Syntheses vol.52, pp.7, 2012, https://doi.org/10.1002/ijch.201100164